- Home
- SVRA vs KMDA Comparison
SVRA vs KMDA Comparison
Compare SVRA & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- KMDA
- Stock Information
- Founded
- SVRA 2007
- KMDA 1990
- Country
- SVRA United States
- KMDA Israel
- Employees
- SVRA N/A
- KMDA N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- KMDA Health Care
- Exchange
- SVRA Nasdaq
- KMDA Nasdaq
- Market Cap
- SVRA 433.8M
- KMDA 443.4M
- IPO Year
- SVRA N/A
- KMDA N/A
- Fundamental
- Price
- SVRA $2.58
- KMDA $7.72
- Analyst Decision
- SVRA Buy
- KMDA Strong Buy
- Analyst Count
- SVRA 5
- KMDA 2
- Target Price
- SVRA $5.60
- KMDA $13.00
- AVG Volume (30 Days)
- SVRA 1.3M
- KMDA 55.0K
- Earning Date
- SVRA 08-11-2025
- KMDA 08-13-2025
- Dividend Yield
- SVRA N/A
- KMDA 2.60%
- EPS Growth
- SVRA N/A
- KMDA 31.21
- EPS
- SVRA N/A
- KMDA 0.28
- Revenue
- SVRA N/A
- KMDA $167,235,000.00
- Revenue This Year
- SVRA N/A
- KMDA $14.51
- Revenue Next Year
- SVRA N/A
- KMDA $9.31
- P/E Ratio
- SVRA N/A
- KMDA $28.31
- Revenue Growth
- SVRA N/A
- KMDA 11.83
- 52 Week Low
- SVRA $1.89
- KMDA $5.08
- 52 Week High
- SVRA $4.74
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- SVRA 59.80
- KMDA 53.97
- Support Level
- SVRA $2.25
- KMDA $7.64
- Resistance Level
- SVRA $2.39
- KMDA $7.91
- Average True Range (ATR)
- SVRA 0.15
- KMDA 0.18
- MACD
- SVRA 0.04
- KMDA -0.02
- Stochastic Oscillator
- SVRA 88.61
- KMDA 50.00
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.